廠家阿法骨化醇生產(chǎn)歷史30年以上。阿法骨化醇已受理,已完成質(zhì)量復(fù)核。阿法骨化醇適用于防治骨質(zhì)疏松癥,甲狀旁腺功能亢進(jìn)(伴有骨病者)、甲狀旁腺功能減退、營(yíng)養(yǎng)和吸收障礙引起的佝僂病和骨軟化癥、假性缺鈣(D-依賴型Ⅰ)的佝僂病和骨軟化癥等。
安森博有近二十年進(jìn)口藥品注冊(cè)經(jīng)驗(yàn),80多個(gè)進(jìn)口藥品成功注冊(cè)案例。
業(yè)務(wù)范圍:1、進(jìn)口藥品代理;2、進(jìn)口藥品注冊(cè)委托服務(wù);3、尋找進(jìn)口制劑國(guó)內(nèi)銷(xiāo)售合作伙伴。
如您對(duì)我們的進(jìn)口原料藥感興趣,只需采購(gòu)即可,我們負(fù)責(zé)進(jìn)口原料藥注冊(cè)等。目前我公司已有近30個(gè)進(jìn)口原料藥在CDE排隊(duì)待審,50多個(gè)進(jìn)口原料藥的資料在整理中。已有60多家國(guó)內(nèi)制劑廠采購(gòu)我們的原料藥。
我們代理的進(jìn)口制劑,已經(jīng)在歐美已經(jīng)或即將上市銷(xiāo)售,質(zhì)量可靠,期待與您合作。
We are a trade company. We are very strong in registration and promotion of import drugs in China, with decades of registration experience and over 86 Licenses procured successfully.
We submitted about 10 import drug applications per year since 2011;
Our knowledge, experience and good working relationship with the regulatory department help us to speed up regulatory approvals and to provide sound support for our formulation customers.
We procured 5 new IDLs in 2010, among which one license was obtained within 10 months and another was obtained within 12 months.
We do not manufacture API and formulation, only focus on registration and promotion of import drug in China.
廠家阿法骨化醇生產(chǎn)歷史30年以上。阿法骨化醇已受理,已完成質(zhì)量復(fù)核。阿法骨化醇適用于防治骨質(zhì)疏松癥,甲狀旁腺功能亢進(jìn)(伴有骨病者)、甲狀旁腺功能減退、營(yíng)養(yǎng)和吸收障礙引起的佝僂病和骨軟化癥、假性缺鈣(D-依賴型Ⅰ)的佝僂病和骨軟化癥等。
產(chǎn)品名稱參考價(jià)
健康減肥進(jìn)口原料藥新利司他銷(xiāo)售價(jià)格
面議在線詢價(jià)*您想獲取產(chǎn)品的資料:
個(gè)人信息: